Pacific Edge seeks $35.3M at 6.2% discount to fund US growth, eyes Singapore

Pacific Edge seeks $35.3M at 6.2% discount to fund US growth, eyes Singapore
By Fiona Rotherham June 5 (BusinessDesk) - Pacific Edge, the listed cancer diagnostics company, is planning a $35.3 million renounceable rights offer at a 6.2 percent discount to fund its US growth strategy, potentially launch into Singapore as a gateway to South East Asia, and complete commercialisation of its third and fourth Cxbladder tests. Under the offer, shareholders can subscribe for two new shares for every 11 held as at June 9 for 61 cents apiece. Pacific Edge shares last traded at 65 cents, down nearly 23 percent this year....